Results of Operations and Financial Condition. On August 5, 2026, Ginkgo Bioworks Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026. A copy of the announcement is furnished with this Current Report on Form 8-K as Exhibit 99.1. Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkg…

Results of Operations and Financial Condition. On May 7, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Completion of Acquisition or Disposition of Assets. On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”) completed the previously announced transaction (the “Transaction”) with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchaser”) pursuant to the Stock Purchase Agreement, dated as of February 26, 2026 (the “Purchase Agreement”), by and among the Seller, the Company, the Purchaser and Ginkgo B…

Entry into a Material Definitive Agreement. On February 26, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Tower Biosecurity, Inc. (the “Purchaser”) and Ginkgo Biosecurity, LLC (“Biosecurity”). Subject to the terms and conditions of the Purchase Agreement, the Seller will contribute to the Purchaser all of the issued and outstanding equity interests of…

Results of Operations and Financial Condition. On February 26, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2025 and year ended December 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

President, Chief Operating Officer — Dr. Reshma Shetty: Dr. Reshma Shetty is transitioning her Chief Operating Officer duties to Jennifer Wipf and Dr. Jason Kelly while remaining as President and a Board member.

Results of Operations and Financial Condition. On November 6, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Entry into a Material Definitive Agreement. On September 4, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Allen & Company LLC (“Allen”), who is acting as the sales agent (the “Agent”). Pursuant to the Sales Agreement, the Company may sell, at its option, shares of its Class A common stock (the “Class A Common Stock”) up to an aggregate offering price of $100,000,000 (the “Shares”) through or directly to the Agent in one or mor…

Other Events. On May 27, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) entered into a Stipulation and Agreement of Settlement (the “Stipulation of Settlement”) to resolve certain stockholder derivative actions commenced nominally on behalf of the Company against certain individual defendants entitled: (i) Hu v. Baker et al., Case No. 4:23-cv-02077-KAW (N.D. Cal.); (ii) Bowers v. Kelly et al., 4:23-cv-05396-KAW (N.D. Cal.); and (iii) In re Ginkgo Bioworks Holdings, Inc. Stockholder Deri…

Results of Operations and Financial Condition. On August 7, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Chief Financial Officer and principal financial officer — Mark Dmytruk: Mark Dmytruk resigned to accept a position at another organization.

Results of Operations and Financial Condition. On May 6, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Results of Operations and Financial Condition. On February 25, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2024 and year ended December 31, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Director — Dr. Arie Belldegrun: Dr. Arie Belldegrun resigned from his position as a director of the Board.

Results of Operations and Financial Condition. On November 12, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 3, 2024, the New York Stock Exchange (the “NYSE”) notified Ginkgo Bioworks Holdings, Inc. (the “Company”), and, on September 4, 2024, publicly announced, that the NYSE has determined to (a) commence proceedings to delist the Company’s public warrants which were previously issued in connection with Soaring Eagle Acquisition Corp.’s initial public offering (the “Warrants”), each War…

of this Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements related to the Company’s expected operating expense reductions, the expected timing of such reduction and the charges and financial impact associated with such reductions, and the timing of headcount reductions. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate…

Results of Operations and Financial Condition. On August 8, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

of this Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements related to the Company’s expected operating expense reductions, the expected timing and effect of such reduction, the charges and financial impact associated with such reductions, and the timing of headcount reductions. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “an…

of this Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements related to the Company’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, the Company’s ability to continue to comply with applicable listing standards of the NYSE, and any potential plans of the Company to cure the stock price deficiency. These forward-looking statements generally…

of this Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements related to the Company’s expected operating expense reductions, the expected timing of such reduction and the charges and financial impact associated with such reductions, and the timing of headcount reductions. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate…

Results of Operations and Financial Condition. On May 9, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Changes in Registrant’s Certifying Accountant. On February 1, 2024, the Audit Committee (“Audit Committee”) of the Board of Directors of Ginkgo Bioworks Holdings, Inc. (the “Company”) authorized management to initiate a request-for-proposal process, soliciting, and subsequently receiving, proposals from three leading national accounting firms to provide audit services to the Company as its independent registered public accounting firm for the fiscal year ending December 31, 2024. Subsequent t…

Results of Operations and Financial Condition. On February 29, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2023 and year ended December 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.